Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma

Armand, Philippe; Janssens, Ann; Gritti, Giuseppe; Radford, John; M. Timmerman, John; Pinto, Antonio; Mercadal Vilchez, Santiago; Johnson, Peter; Cunningham, David; P. Leonard, John; J. Rodig, Scott; Martin‐Regueira, Patricia; Sumbul, Anne; Samakoglu, Selda; Tang, Hao; M. Ansell, Stephen

doi:10.1182/blood.2019004753

Public

Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma

Published in Blood • Sep 1, 2020

Authors:

Philippe Armand

Ann Janssens

Giuseppe Gritti

Abstract

Nivolumab, an anti-programmed death-1 (PD-1) monoclonal antibody, showed promising activity in relapsed or refractory (R/R) follicular lymphoma (FL) in a phase 1 study. We conducted a phase 2 trial to further evaluate its efficacy and safety in patients with R/R FL and to explore biomarkers of respo...

Subject

Nivolumab

Medicine

Follicular lymphoma

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!